STOCK TITAN

Royalty Pharma (NASDAQ: RPRX) insider sale notice — 3,045 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Royalty Pharma plc filed a Form 144 reporting the proposed sale of 3,045 shares of Common Stock on 05/13/2026. The notice lists Merrill Lynch, 225 Liberty Street, Floor 37, New York as the broker and references the vesting of restricted stock unit awards granted under the issuer equity compensation plan.

Positive

  • None.

Negative

  • None.

Insights

Routine affiliate resale following RSU vesting; broker-listed sale of 3,045 shares.

The filing documents a proposed disposition of 3,045 shares of Common Stock dated 05/13/2026, tied to the vesting of restricted stock unit awards. The broker is listed as Merrill Lynch at 225 Liberty Street.

The notice is a regulatory disclosure of an intended sale method and quantity; timing and execution details beyond the listed date are not further detailed in the excerpt. Subsequent transaction reporting would show completion and actual proceeds.

Form type Form 144 insider resale notice
Shares proposed for sale 3,045 shares 05/13/2026
CUSIP 443274104 Common Stock identifier
Broker address floor 225 Liberty Street, Floor 37 Merrill Lynch, New York
restricted stock unit awards financial
"Vesting of restricted stock unit awards"
Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.
Form 144 regulatory
"Filer Information | 144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
vesting financial
"05/13/2026 | Vesting of restricted stock unit awards"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for RPRX show?

The Form 144 shows a proposed sale of 3,045 shares of Royalty Pharma common stock, dated 05/13/2026, tied to RSU vesting under the company's equity compensation plan.

Who is the listed broker on the RPRX Form 144?

The broker listed is Merrill Lynch with address 225 Liberty Street, Floor 37, New York, as shown on the Form 144 filing for the proposed sale of 3,045 shares.

Why were the 3,045 RPRX shares available for sale?

The filing references the vesting of restricted stock unit awards granted under the issuer equity compensation plan, which made the 3,045 shares available for disposition on 05/13/2026.

Does the Form 144 indicate the sale was completed?

The Form 144 reports a proposed disposition dated 05/13/2026 for 3,045 shares. Completion and proceeds would be shown in subsequent transaction reports if and when the sale occurs.